Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs

Abstract

There are several routes of administration to the brain, including intraparenchymal, intraventricular, and subarachnoid injections. The blood-brain barrier (BBB) impedes the permeation and access of most drugs to the central nervous system (CNS), and consequently, many neurological diseases remain undertreated. For past decades, to circumvent this effect, several nanocarriers have been developed to deliver drugs to the brain. Importantly, intranasal (IN) administration can allow direct delivery of drugs into the brain through the anatomical connection between the nasal cavity and brain without crossing the BBB. In this regard, dendrimers may possess great potential to deliver drugs to the brain by IN administration, bypassing the BBB and reducing systemic exposure and side effects, to treat diseases of the CNS. In this original concise review, we highlighted the few examples advocated regarding the use of dendrimers to deliver CNS drugs directly via IN. This review highlighed the few examples of the association of dendrimer encapsulating drugs ( e.g. , small compounds: haloperidol and paeonol; macromolecular compounds: dextran, insulin and calcitonin; and siRNA) using IN administration. Good efficiencies were observed. In addition, we will present the in vivo effects of PAMAM dendrimers after IN administration, globally, showing no general toxicity.

Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity

“…Studies regarding the binding of VivaGel ® to SARS-CoV-2 spike protein, thus blocking the interaction of the virus with the host human membrane ACE2 protein (the first event of infection), are ongoing, as are investigations into its use as an antiviral agent against COVID-19 via nasal or inhalational administration [ 97 ]. One of the important advantages of dendrimers is that they can reach the systemic circulation via multiple administration routes, such as oral, intravenous, transdermal, topical ocular [ 98 ] ( Figure 4 ) and nasal routes [ 99 ]. In an excellent review, Kuzmova and Minko highlighted the strong advantages of nanotechnology approaches for inhalation treatment of lung diseases [ 100 ].…”

The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers

“…Co-delivery systems for drug delivery come in many designs. They may comprise carriers, where one or more drugs are packaged into liposomes, nanoparticles, hydrogels, dendrimers, or other vehicles [119,120], and some of these are being developed specifically for the purpose of intranasal delivery to reach the brain via the nose-to-brain route [121,122]. Studies with POH have also revealed characteristics that make this monoterpenoid suitable for the purpose of transporting other drugs directly to the brain via the nose-to-brain route.…”

New Insights Regarding Diagnosis and Medication for Schizophrenia Based on Neuronal Synapse–Microglia Interaction

“…It is necessary for drugs to reach the brain for the treatment of schizophrenia. With respect to recent drug delivery technology into the brain, conjugations by BBB-penetrating peptides [ 152 , 153 ] and intranasal administration have been developed [ 154 , 155 ]. The combination of the synapse-protecting reagent and brain delivery methods could be used to treat schizophrenia.…”